Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis

Journal of Paediatrics and Child Health

Volumn 42, Issue 10, 2006, Pages 601-605

  Massie, John ^a   Cranswick, Noel ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cystic fibrosis; Pharmacokinetics; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DEMOGRAPHY; DRUG CLEARANCE; DRUG HALF LIFE; HOSPITAL ADMISSION; HUMAN; INFANT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; TOBRAMYCIN;

EID: 33748419349     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2006.00944.x     Document Type: Article

References (32)

1. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45.
2. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
3. Beaubien AR, Ormsby E, Bayne A et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob. Agents. Chemother. 1991; 35: 1070-4.
4. Powell SH, Thompson WL, Luthe MA et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J. Infect. Dis. 1983; 147: 918-32.
5. Henley CM III, Schacht J. Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology 1988; 27: 137-46.
6. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP 1989; 23: 788-94.
7. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob. Agents. Chemother. 1991; 35: 399-405.
8. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur. J. Clin. Microbiol. Infect. Dis. 1989; 8: 761-9.
9. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J. Hosp. Infect. 1991; 18 (Suppl. A): 117-29.
10. Pechere JC, Craig WA, Meunier F. Once daily dosing of aminoglycoside: one step forward. J. Antimicrob. Chemother. 1991; 27 (Suppl. C): 149-52.
11. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 1996; 335: 179-88.
12. Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin. Pharmacokinet. 1993; 24: 496-506.
13. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988; 35: 542-78.
14. Hsu MC, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatric Infect. Dis. 1984; 3: 526-9.
15. Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. J. Pediatr. 1979; 94: 163-4.
16. Kelly HB, Menendez R, Fan L, Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J. Pediatr. 1982; 100: 318-21.
17. Vic P, Ategbo S, Turck D et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch. Dis. Childhood 1998; 78: 536-9.
18. Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J. Antimicrob. Chemother. 1996; 37: 1040-2.
19. Master V, Roberts GW, Coulthard KP et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr. Pulmonol. 2001; 31: 367-76.
20. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob. Agents. Chemother. 2000; 44: 809-13.
21. Bragonier R, Brown NM. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J. Antimicrob. Chemother. 1998; 42: 103-6.
22. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur. Respir. J. 2002; 19: 303-9.
23. Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 819-23.
24. Tan KH, Bunn H. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane Library 2. Oxford, Update Software. 2003.
25. Carapetis JR, Jaquiery AL, Buttery JP et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr. Infect. Dis. J. 2001; 20: 240-6.
26. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 1997; 62: 392-9.
27. Wood PJ, Ioannides-Demos LL, Li SC et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996; 51: 369-73.
28. Sanchez-Alcaraz A, Vargas A, Quintana MB et al. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J. Clin. Pharmacy Ther. 1998; 23: 367-73.
29. Bates RD, Nahata MC, Jones JW et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997; 112: 1208-13.
30. Quesnel LB, Jaran AS, Braganza JM. Antibiotic accumulation and membrane trafficking in cystic fibrosis cells. J. Antimicrob. Chemother. 1998; 41: 215-21.
31. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 67-95.
32. Boeckman A, Sheiner L, Beal S. NONMEM User's Guide. UCSF, San Francisco, CA: NONMEM Project Group, 1994.